CRISPR Therapeutics CRSP Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- CRISPR Therapeutics (CRSP) reported comprehensive income (loss), net of tax, attributable to parent of -$129.69M in Q1 2026.
- How has CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent increased by 3.0% year-over-year, from -$133.7M to -$129.69M.
- What is the long-term trend for CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a -6.4% compound annual growth rate (CAGR), from -$660.75M to -$578.62M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This represents the total change in equity from non-owner sources, including net income and other comprehensive income items like foreign currency adjustments and unrealized gains on securities. It provides a more holistic view of the company's financial health than net income alone by capturing broader economic impacts. Investors use this to evaluate the total impact of all financial activities on the company's net worth.